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Letters
Predicting and Preventing Visual Impairment
and Blindness by Incorporating Individual
Progression Velocity in Glaucoma Care
Taking into account age and life expectancy in glaucoma care
seems mandatory, given the large proportion of glaucoma
patients who will not suffer serious visual impairment at the
time of death, reported by Saunders et al.1 in the January 2014
issue. Only 5.2% of patients were predicted to progress to
statuary blindness and another 10.4% to visual impairment.
It is not easy to incorporate the findings of Saunders et al.
correctly in clinical decision making. Current prediction
models do not allow for a reliable early identification of those
patients who will become visually impaired or blind. This
reassures the current need of initially treating most glaucoma
patients, an approach that has been shown to be very cost-
effective.2,3 It also reassures that those who are at risk of visual
impairment must be identified during follow-up to personalize
the treatment intensity in a later stage. A tool to identify
patients at risk of visual impairment is not available in current
perimeter software and became available only recently for
clinicians.4 Saunders et al.1 reported that those with a
presenting mean deviation (MD) better than -6 dB (early
glaucoma) are at a small risk. This rule, however, is only valid
within the context of the authors’ data collection, which was
performed among patients treated in regular care in the United
Kingdom. If clinicians take the message literally and delay or
taper treatment in early glaucoma, visual impairment or
blindness may no longer be rare in this group. In this letter
we will address these issues from a clinician perspective.
In 2011, we published a tool4 that can be used to estimate
the probability of becoming visually impaired before dying, for
newly diagnosed patients (that is, in a situation where the
individual progression velocity is not yet known). Figures 1A
(men) and 1B (women) show this tool again, now with the
baseline data from the cohort of the Groningen Longitudinal
Glaucoma Study (GLGS; described in detail previously5,6)
plotted in the graphs. A random eye was chosen if both eyes
were available. If the combination of age and MD is in the red
area, the probability of becoming visually impaired before dying
exceeds 2.5%, even if treated. In the green area, this probability
is less than 2.5% even if left untreated. Visually impaired was
defined as an MD of -20 dB or worse. It can be seen that at
baseline most of the patients were in the red area. This
indicates that it is not easy to identify patients at risk for
blindness already at the time of diagnosis.
After at least five years of perimetric follow-up, individual
progression velocities can be determined7 and this allows for a
refined estimate of the probability of becoming visually
impaired before dying. We published another tool to help the
clinician with this estimate as well.4 We applied the latter tool
to all patients from the GLGS with at least five years of
perimetric follow-up (n ¼ 160, mean follow-up 9.4 years).8
Figure 2A presents these patients as either red or green dots,
depending on their end-of life MD (red, end-of-life MD -20 dB
or worse; green, better than -20 dB), calculated from
individual progression velocities and the P95 of residual life
expectancies (longevity). Figure 2B presents the corresponding
results for median residual life expectancy. Clearly, there is a
decrease in the percentage of patients at risk of reaching visual
impairment compared to the situation in which the progression
velocity is not yet known (Fig. 1). Furthermore, in Figure 2
there is a considerable overlap in age and MD for patients at risk
and those not at risk of visual impairment, indicating that it is
not possible to identify patients at risk merely by means of their
age and MD. These findings illustrate the added value of the
determination of individual progression velocities.
Saunders et al.1 found that patients with early glaucoma at
presentation were relatively spared from visual impairment. In
agreement with them, there are no red dots in Figure 2B above
-6 dB. However, as mentioned above, this is not a disease
property, but a context-specific observation. Figure 3A presents
the same calculations as Figure 2A, but now with the individual
progression velocities tripled for all patients. In this situation, a
presenting MD of -6 dB or better is no longer a guarantee for
preserved sight. A tripled progression velocity is not unrealistic.
In fact, it corresponds with a situation where the mean IOP
during follow-up is only approximately 4 mm Hg higher. In the
GLGS, the median (P90) progression velocity was -0.20
(-0.80) dB/y at a mean (SD) IOP during follow-up of 15 (3)
mm Hg.8,9 In a clinical cohort from Malmo, these values were
-0.62 (-2.0) dB/y at an IOP of 19 (5) mm Hg.10 Findings in
agreement with the GLGS also were reported from a large
clinical cohort in Canada and the Canadian Glaucoma Study
(Chauhan B, et al. IOVS 2013;54:ARVO E-Abstract 2635). The
influence of a tripled progression velocity remains clearly
visible if we repeat the analysis with median residual life
expectancy rather than the 95th percentile (Figs. 2B, 3B) and
this is in line with the finding that the lifetime risk of open-
angle glaucoma blindness increases with IOP.11
In conclusion, from a health-economical point of view, we
want to know the percentage of glaucoma patients that will
become visually impaired or blind, as was calculated by
Saunders et al.1 For a newly-diagnosed individual patient, and
his/her physician, this information provides a global prognosis,
but it will not have direct therapeutic consequences, since it is
virtually impossible to say if this specific patient in the
consulting room will become visually impaired or not. Most
glaucoma patients deserve initially a tight IOP control, and this
is a highly cost-effective approach even if only a small
percentage eventually will become blind.2,3 Taking into
account life expectancy in glaucoma care is possible as soon
as the individual progression velocity is known. In our hospital,
the estimated end-of-life MD (Fig. 4) is available in our
computer patient record, both for longevity (95th percentile
of residual life expectancy, Fig. 4A) and for median residual life
expectancy (Fig. 4B). This gives the clinician, besides MD, age,
and progression velocity, information about the way the
individual patient is heading and can be used to apply a less
strict IOP control regimen in some patients. For the majority of
patients, however, a tight IOP control and follow-up seem
mandatory and for them, knowing that only 5.2% of patients
will progress to statuary blindness and another 10.4% to visual
impairment is a reassuring fact.
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FIGURE 1. Probability of becoming visually impaired before dying for men (A) and women (B). If the combination of age and current MD brings the
patient in the red area, the probability of becoming visually impaired before dying exceeds 2.5%, even if treated. In the orange area less than 2.5% if
treated but more than 2.5% if untreated. In the green area this probability is less than 2.5% even if untreated. Visually impaired was defined as an MD
of -20 dB. Dots represent patients enrolled in the GLGS.
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FIGURE 2. Risk of becoming blind, given the current MD, age, and rate of progression, for the 95th percentile of life expectancy (longevity; [A]) and
mean life expectancy (B). Red dots represent patients enrolled in the GLGS who will become visually impaired, green dots those who will not.
Visually impaired was defined as an MD of -20 dB.
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FIGURE 3. Risk of becoming blind, given the current MD, age, and rate of progression tripled, for the 95th percentile of life expectancy (longevity;
[A]) and mean life expectancy (B). See also legends for Figure 2.
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FIGURE 4. Distribution of end-of-life MD as calculated for all patients
enrolled in the GLGS, given current age, MD, and progression rate for
the 95th percentile of life expectancy (longevity; [A]) and mean life
expectancy (B).
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